T1 Biomarker 1133 1138 ctDNA
T2 Biomarker 782 794 panobinostat
T3 Protein 840 849 rituximab
T4 Protein 725 738 plasma sample
T5 Condition 1483 1492 mutations
T6 Gene 564 570 exomes
T7 Intervention 397 403 orally
T8 Organism 992 1000 patients
T9 Condition 1482 1493  mutations 
T10 Condition 54 59 tumor
T11 Organism 453 461 patients
T12 Condition 1435 1441  DLBCL
T13 Biomarker 708 713 ctDNA
T14 Organism 754 762 patients
T15 Biomarker 1361 1373 panobinostat
T16 Disease 342 350 toxicity
T17 Biomarker 1222 1227 ctDNA
T18 Protein 235 239 HDIs
T19 Condition 24 46 large B-cell lymphoma 
T20 Gene 1028 1033 genes
T22 Condition 531 536 DLBCL
T23 Condition 69 78 mutations
T24 Gene 548 553 genes
T25 Protein 194 198 HDIs
T26 Condition 697 702 tumor
T27 Biomarker 1529 1534 ctDNA
T28 Condition 68 79  mutations 
T29 Gene 490 497 de novo
T30 Protein 1496 1501 MEF2B
T31 Condition 47 52 DLBCL
T32 Condition 685 706 circulating tumor DNA
T33 Organism 1186 1194 patients
T34 Condition 530 536  DLBCL
T35 Protein 1153 1166 plasma sample
T36 Protein 1070 1075 MEF2B
T37 Biomarker 354 366 panobinostat
T38 Protein 436 445 rituximab
T39 Condition 1045 1054 mutations
T40 Condition 53 108  tumors contain mutations in histone-modifying enzymes 
T41 Protein 718 739 serial plasma samples
T42 Condition 597 602 tumor
T43 Protein 941 942 â€œ
T45 Condition 81 96  histone-modify
T46 Organism 1413 1421 patients
T47 Protein 626 635 molecular
